SG11201609206QA - Tal-effector nuclease for targeted knockout of the hiv co-receptor ccr5 - Google Patents

Tal-effector nuclease for targeted knockout of the hiv co-receptor ccr5

Info

Publication number
SG11201609206QA
SG11201609206QA SG11201609206QA SG11201609206QA SG11201609206QA SG 11201609206Q A SG11201609206Q A SG 11201609206QA SG 11201609206Q A SG11201609206Q A SG 11201609206QA SG 11201609206Q A SG11201609206Q A SG 11201609206QA SG 11201609206Q A SG11201609206Q A SG 11201609206QA
Authority
SG
Singapore
Prior art keywords
tal
hiv
effector nuclease
receptor ccr5
targeted knockout
Prior art date
Application number
SG11201609206QA
Other languages
English (en)
Inventor
Ulrike Mock
Boris Fehse
Original Assignee
Advanced Gene & Cell Technologies Llc Agct Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53761910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201609206Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Advanced Gene & Cell Technologies Llc Agct Llc filed Critical Advanced Gene & Cell Technologies Llc Agct Llc
Publication of SG11201609206QA publication Critical patent/SG11201609206QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201609206QA 2014-05-07 2015-05-04 Tal-effector nuclease for targeted knockout of the hiv co-receptor ccr5 SG11201609206QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102014106327.9A DE102014106327A1 (de) 2014-05-07 2014-05-07 TAL-Effektornuklease zum gezielten Knockout des HIV-Korezeptors CCR5
PCT/DE2015/200295 WO2015169314A1 (de) 2014-05-07 2015-05-04 Tal-effektornuklease zum gezielten knockout des hiv-korezeptors ccr5

Publications (1)

Publication Number Publication Date
SG11201609206QA true SG11201609206QA (en) 2016-12-29

Family

ID=53761910

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201609206QA SG11201609206QA (en) 2014-05-07 2015-05-04 Tal-effector nuclease for targeted knockout of the hiv co-receptor ccr5

Country Status (15)

Country Link
US (1) US20170152496A1 (es)
EP (1) EP3140398B1 (es)
JP (1) JP2017514525A (es)
KR (1) KR102324460B1 (es)
AU (1) AU2015255366B2 (es)
CA (1) CA2948198C (es)
CL (1) CL2016002737A1 (es)
DE (1) DE102014106327A1 (es)
DK (1) DK3140398T3 (es)
EA (1) EA036375B1 (es)
ES (1) ES2757604T3 (es)
IL (1) IL248718B (es)
MX (1) MX2016014556A (es)
SG (1) SG11201609206QA (es)
WO (1) WO2015169314A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018251150B2 (en) 2017-04-13 2024-05-09 Albert-Ludwigs-Universität Freiburg New sequence specific reagents targeting CCR5 in primary hematopoietic cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010327998B2 (en) 2009-12-10 2015-11-12 Iowa State University Research Foundation, Inc. TAL effector-mediated DNA modification
CA2798988C (en) 2010-05-17 2020-03-10 Sangamo Biosciences, Inc. Tal-effector (tale) dna-binding polypeptides and uses thereof
EP2392208B1 (en) 2010-06-07 2016-05-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use
EP2580331A4 (en) 2010-06-14 2013-11-27 Univ Iowa State Res Found Inc NUCLEASE ACTIVITY OF THE TAL EFFECTOR AND FUSION PROTEIN FOKI
WO2012093833A2 (en) 2011-01-03 2012-07-12 Toolgen Incorporation Genome engineering via designed tal effector nucleases
WO2013074999A1 (en) 2011-11-16 2013-05-23 Sangamo Biosciences, Inc. Modified dna-binding proteins and uses thereof
US10815500B2 (en) 2012-06-05 2020-10-27 Cellectis Transcription activator-like effector (TALE) fusion protein
CN103724410B (zh) 2012-10-12 2017-10-03 清华大学 一类调控ccr5和cxcr4基因的融合蛋白及方法

Also Published As

Publication number Publication date
WO2015169314A1 (de) 2015-11-12
MX2016014556A (es) 2017-05-04
IL248718B (en) 2020-05-31
KR20170002542A (ko) 2017-01-06
EP3140398B1 (de) 2019-08-28
AU2015255366B2 (en) 2021-04-01
AU2015255366A1 (en) 2016-11-24
CA2948198C (en) 2023-11-21
KR102324460B1 (ko) 2021-11-09
JP2017514525A (ja) 2017-06-08
ES2757604T3 (es) 2020-04-29
DK3140398T3 (da) 2019-11-25
EA201650071A1 (ru) 2017-03-31
NZ725905A (en) 2021-08-27
CL2016002737A1 (es) 2017-07-14
DE102014106327A1 (de) 2015-11-12
EA036375B1 (ru) 2020-11-02
US20170152496A1 (en) 2017-06-01
CA2948198A1 (en) 2015-11-12
IL248718A0 (en) 2017-01-31
EP3140398A1 (de) 2017-03-15

Similar Documents

Publication Publication Date Title
GB2530831B (en) Targeted mutations
SG11201700070QA (en) Modulators of toll-like receptors for the treatment of hiv
HK1246776A1 (zh) 用於hiv治療的異喹啉化合物
IL247624A0 (en) Intentional healing
AP00744S1 (en) Headset
HK1226232A1 (zh) 萬能揚聲器
HK1257272A1 (zh) 治療hiv的工具
IL246956A0 (en) targeted therapies
EP3223858A4 (en) Tlr9 targeted cytotoxic agents
ZA201608686B (en) Interseparation of metals
HK1223624A1 (zh) 替諾福韋的固體形式
IL248718B (en) Nuclease tal-effector for targeting the ccr5 receptors of hiv
PL3131633T3 (pl) Pochodne MMF etylenoglikoli
GB201417347D0 (en) Prodrugs of delanzomib
GB201417348D0 (en) Prodrugs of lxazomib
GB201417343D0 (en) Prodrugs of bortezomib
GB201421832D0 (en) Headsets
GB201414132D0 (en) Prodrugs of bortezomib
AU2014905072A0 (en) Structured Globules
TWM489582U (en) Improved structure of cup
GB201415152D0 (en) Omega crane
AU2014903428A0 (en) Treatment of HIV
GB201407898D0 (en) Proximity